User profiles for J. Cloos

Jacqueline Cloos

Research coordinator, Hematology, VU University Medical Center,
Verified email at vumc.nl
Cited by 15815

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

…, MC Béné, F Buccisano, J Cloos… - Blood, The Journal …, 2018 - ashpublications.org
Measurable residual disease (MRD; previously termed minimal residual disease) is an
independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is …

[HTML][HTML] The role of alternative splicing in cancer: From oncogenesis to drug resistance

…, G Jansen, GJL Kaspers, E Giovannetti, J Cloos - Drug Resistance …, 2020 - Elsevier
Alternative splicing is a tightly regulated process whereby non-coding sequences of pre-mRNA
are removed and protein-coding segments are assembled in diverse combinations, …

Molecular basis of resistance to proteasome inhibitors in hematological malignancies

…, YG Assaraf, S Zweegman, GJL Kaspers, J Cloos - Drug resistance …, 2015 - Elsevier
Over the past decade, the proteasome inhibitor bortezomib (Velcade) has not only gained a
cornerstone position in the treatment of hematological malignancies, particularly multiple …

Cell sensitivity assays: the MTT assay

J Van Meerloo, GJL Kaspers, J Cloos - Cancer cell culture: methods and …, 2011 - Springer
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay is based on
the conversion of MTT into formazan crystals by living cells, which determines mitochondrial …

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

…, C Thiede, K Döhner, GJ Roboz, J Cloos - Blood, The Journal …, 2021 - ashpublications.org
Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML)
that is used for prognostic, predictive, monitoring, and efficacy-response assessments. …

[HTML][HTML] Molecular minimal residual disease in acute myeloid leukemia

…, PL Gradowska, R Meijer, J Cloos… - … England Journal of …, 2018 - Mass Medical Soc
Background Patients with acute myeloid leukemia (AML) often reach complete remission, but
relapse rates remain high. Next-generation sequencing enables the detection of molecular …

[HTML][HTML] Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features

…, D Troost, NS Meeteren, HN Caron, J Cloos… - PloS one, 2008 - journals.plos.org
Background Medulloblastoma is the most common malignant brain tumor in children.
Despite recent improvements in cure rates, prediction of disease outcome remains a major …

Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein

…, NE Franke, YG Assaraf, J Cloos… - Blood, The Journal …, 2008 - ashpublications.org
The proteasome inhibitor bortezomib is a novel anticancer drug that has shown promise in
the treatment of refractory multiple myeloma. However, its clinical efficacy has been …

Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia

…, I Wlodarska, B Cauwelier, J Cloos, J Soulier… - Nature …, 2013 - nature.com
T-cell acute lymphoblastic leukemia (T-ALL) is caused by the cooperation of multiple
oncogenic lesions 1 , 2 . We used exome sequencing on 67 T-ALLs to gain insight into the …

[PDF][PDF] In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma

…, D Geerts, GJL Kaspers, WP Vandertop, J Cloos… - Cancer cell, 2010 - cell.com
Kinases execute pivotal cellular functions and are therefore widely investigated as potential
targets in anticancer treatment. Here we analyze the kinase gene expression profiles of …